rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known
hospitals in China. In order to report the efficacy and safety of Recombinant Human
thrombopoietin combining with Rituximab for the treatment of adults with refractory immune
thrombocytopenia (ITP), compared to conventional Rituximab therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Shandong University
Collaborators:
First Hospital of China Medical University Shandong Provincial Hospital Shenzhen Second People's Hospital The Affiliated Hospital of the Chinese Academy of Military Medical Sciences The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Dalian Medical University